Methods and Data
The authors analyzed a big database, selecting almost 20% of a universe of 17.000 patients because they had all clinical data in their electronic registries in the period 2010-2016. They designed their analytical unit as 120 day period containing 8 fortnightly hemoglobin levels of each of the 3349 selected patients. These patients also contributed with some other clinical variables to the final analysis. Then, they correctly standardized units of measurement of lab tests and ESAs doses. What proportion of those patients did not use ESAs? Were they included in the analysis? Or the target population for this study was just those using ESAs? They elaborated their classification tool as a three classes of anemia control without specification how they chose those classes, but it appears they indeed selected three thirds. The selected statistical tool, the Durbin-Skilling-Mack test, is appropriate and accounts for the missing values of the clinical variables other than the hemoglobin levels. But, I do not have completely clear if this test assumption of randomly missing values in each class really applies to the database. For example, if a patient in a determined 120-day period develops an infectious event, he will have inflammatory markers done but not in other 120-days period or in winter months, there will be more infectious events than in other seasons.
Results
Some baseline characteristics are well described in Table 3 , but, it is expected that other clinical characteristics that could be related with hemoglobin fluctuations or successful anemia treatment also to be shown. For example, nephropathy, diabetes, vascular disease, dialysis vintage, PTH levels, etc. Table 4 is very illustrative. It suggest that the three classes from the Classification system are real and useful, but, at the same time, it could be unfair to use the proposed classification system to compare dialysis facilities if the classification system does not account for all these issues. For example, just the different ESA doses in the three classes suggest clinical significant differences in the patients.
Discussion
The content of this section is OK and well structured, but I am not sure if this statement (forth line): "The classification grades offer a clear description of the outcome of the respective anaemia management" really applies as the database gave just static information to the authors. They did not even intent to show longitudinal results in single or group patients. I agree with the final remarks that it is necessary to close the gap between clinical guidelines and clinical results. The Classification system elaborated by the authors could contribute to this objective. Other sections, tables and figures are ok.
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REVIEW RETURNED
21-Jun-2017 the scarcity in endogenous erythropoietin (Epo) as the main culprit of anemia and as the clinical administration of Epo has contributed to a better management of CKD patients, in spite of some caveats of cardiovascular adverse events or, even, early mortality. At this point, the authors make the point that healthy people show stable hemoglobin levels and CKD patients do not, and that this issue could contribute to adverse clinical outcomes observed in CKD patients. The next two paragraphs are devoted to show that there is no consensus in the target hemoglobin level to be achieved with Epo or other erythropoiesis stimulating agents (ESA) and the frequent observation of hemoglobin levels fluctuations, related or not to ESA treatment. After this two pages of introduction, the authors manifest their aim: ?Hence, in this article, we will introduce a new classification system for Hb management in patients with haemodialysis in order to easily evaluate the quality of the outcome in terms of exceeding or falling below the predefined Hb target values in predetermined periods?.
GENERAL COMMENTS
At this respect: 1. It is surprising that the aim is to develop a Classification system if, based in the introduction section, it appears that there are no problems in classification or treatment of the anemia of CKD or end stage renal disease (ESRD) patients.
Changes made in the manuscript: Introduction, page 4, line 57: A tool to classify and monitor the amount of Hb data out of range could be useful in many ways: To describe and compare individual patients as well as patient collectives, as a basis for further considerations of e.g. performance of Hb management and finally as an integrative part in a clinical decision support tool. Hence, in this article, we will introduce a new, descriptive classification system for the monitoring of Hb trajectories in patients on haemodialysis treated with ESAs.
Discussion, page 10 line 27: Our goal was to classify the amount of Hb variability and cycling as major problems of Hb management in ESRD patients and to offer a very simple and easily understandable classification system that facilitates to group patients in manageable classes for further consideration.
Hence, the presented classification provides a pragmatic method to evaluate Hb trajectories in terms of exceeding or falling below the predefined Hb target values in predetermined periods for a single patient or a whole dialysis centre.
Statement of the authors:
We tried to make it clear firstly, why we think a classification system is needed and secondly, what we consider to be the goal of our classification system. We are afraid that we are at least partly in some way misunderstood. We tried to clearly state the problems in anaemia management (page 4, line 14 -25, line 48 -57) and therefore are sorry that we apparently were not distinctive enough.
2. To evaluate an outcome it is expected to have longitudinal data.
The underlying data are all longitudinal. We examine data from a time frame of six years in periods of 120 days. We deliberately looked at the data from an objective point of view since we explicitly did not want to value the quality of anaemia management or the comorbidities of the patients. The latter can be done in a particular application of our classification system where longitudinal data are the prerequisite for the classification process.
3. The real aim could be to develop a management tool to facilitate the description of haemoglobin fluctuations in dialysis facilities in order to compare their performances in anaemia treatment. Changes made in the manuscript: Please see above Statement of the authors: This is one of the application possibilities, but as said before, the classification system was not developed in first place to value anaemia treatment but to obtain an overview of patients and as you stated performance of anaemia treatment. The classification system offers the possibility to compare any dialysis centre to our pooled data, representing a kind of standard. The valuation of anaemia treatment and the consideration of comorbidities of patients may then be a second step to evaluate influences on the result of the classification.
Methods and Data
The authors analyzed a big database, selecting almost 20% of a universe of 17.000 patients because they had all clinical data in their electronic registries in the period 2010-2016. They designed their analytical unit as 120 day period containing 8 fortnightly hemoglobin levels of each of the 3349 selected patients. These patients also contributed with some other clinical variables to the final analysis. Then, they correctly standardized units of measurement of lab tests and ESAs doses. What proportion of those patients did not use ESAs? Were they included in the analysis? Or the target population for this study was just those using ESAs? Changes made in the manuscript: Methods and Data -Participating centres, page 5, line 31: From these, only patients on haemodialysis who were treated with ESAs were taken into account. According to the database 60% of patients on haemodialysis were treated with ESAs while for 40% of patients no information on ESA use was given. Those patient presumably did either not receive ESA treatment or respective data were not documented.
Statement of the authors:
We only used data from patients whose treatment with ESAs was documented within the database. Hence, 40% of patients on haemodialysis were either not treated with ESAs or the medication was not documented.
They elaborated their classification tool as a three classes of anemia control without specification how they chose those classes, but it appears they indeed selected three thirds. Changes made in the manuscript: Methods and Data -Proposed classification scheme, page 7, line 38: Three classes with comparable numbers of patients were projected.
The selected statistical tool, the Durbin-Skilling-Mack test, is appropriate and accounts for the missing values of the clinical variables other than the hemoglobin levels. But, I do not have completely clear if this test assumption of randomly missing values in each class really applies to the database. For example, if a patient in a determined 120-day period develops an infectious event, he will have inflammatory markers done but not in other 120-days period or in winter months, there will be more infectious events than in other seasons.
We totally agree that inflammatory markers are done if a patient is suspected to have an infection. Therefore we categorized the respective variables as "Parameters correlated to infections" because these results don't apply for the entire collective but give hints on comorbidities that could partly explain a higher number of Hb values out of range. The missing data we had to account for in this case occur when the laboratory values should have been determined but are missing in the database, either because they were not assessed or were not stored.
Results
Some baseline characteristics are well described in Table 3 , but, it is expected that other clinical characteristics that could be related with hemoglobin fluctuations or successful anemia treatment also to be shown. For example, nephropathy, diabetes, vascular disease, dialysis vintage, PTH levels, etc.
Statement of the authors:
Unfortunately, at the moment we don't have data concerning comorbidities. For the mere -descriptive -evaluation of Hb values out of range it is not necessary to account for comorbidities, this would complicate the placement in the respective grades enormously and restrict usability. But analysing comorbidities can be of interest when applying the classification in a specific case. Table 4 is very illustrative. It suggest that the three classes from the Classification system are real and useful, but, at the same time, it could be unfair to use the proposed classification system to compare dialysis facilities if the classification system does not account for all these issues. For example, just the different ESA doses in the three classes suggest clinical significant differences in the patients. Changes made in the manuscript: Discussion, page 10, line 42: The classification itself is neutral and without any implicit valuation. The application of the classification grades offers a clear description of an individual patient or a patient collective in terms of patients' responsiveness or performance of the respective anaemia management. They allow a valuable overview for long term patients, and for comparing dialysis centres regarding their patient pool.
Statement of the authors: You are exactly right; the proposed classification system should not be used to discredit dialysis facilities. Our classification system is primarily meant as a descriptive tool, not as a valuing tool. Like other classification or grading tools in medicine, it should be neutral. We have worked through our manuscript to emphasize this. The strength of our classification system lies within its convenience which would get lost if multiple other parameters had to be taken into account.
Discussion
The content of this section is OK and well structured, but I am not sure if this statement (forth line): ?The classification grades offer a clear description of the outcome of the respective anaemia management? really applies as the database gave just static information to the authors. They did not even intent to show longitudinal results in single or group patients.
Statement of the authors:
In principle, all information used was longitudinal in several aspects. Patients were followed for at least 120 days, with an average of 8.1 periods (970 days or 2.7 years) per patient. For a further publication we could examine firstly the comorbidities (if we can get the data), as you remarked, and the fluctuations from grade to grade in individual patients or group of patients over time. For the development of the classification system itself, the pooled data with a core set of information was decisive.
I agree with the final remarks that it is necessary to close the gap between clinical guidelines and clinical results. The Classification system elaborated by the authors could contribute to this objective. Other sections, tables and figures are ok Reviewer: 2 Michael Brier University of Louisville, USA Please state any competing interests or state ?None declared?: The reviewer has published in the area of anemia management and has intellectual property used for anemia management.
Please leave your comments for the authors below Introduction, paragraph 1. The authors could improve the manuscript by addressing the need for a classification system for anemia management and how that would impact clinical practice.
Changes made in the manuscript: Introduction, page 4, line 57: A tool to classify and monitor the amount of Hb data out of range could be useful in many ways: To describe and compare individual patients as well as patient collectives, as a basis for further considerations of e.g. performance of Hb management and finally as an integrative part in a clinical decision support tool. Hence, in this article, we will introduce a new, descriptive classification system for the monitoring of Hb management trajectories in patients on haemodialysis treated with ESAs. Discussion, page 10, line 27: Our goal was to classify the amount of Hb variability and cycling as major problems of Hb management in ESRD patients and to offer a very simple and easily understandable classification system that facilitates to group patients in manageable classes for further consideration. Hence, the presented classification provides a pragmatic method to evaluate Hb trajectories in terms of exceeding or falling below the predefined Hb target values in predetermined periods for a single patient or a whole dialysis centre.
We worked through our manuscript to improve this aspect.
Methods. The classification system was developed on 3349 patients from an overall pool of 17,000 patients. No information is provided as to why patients were excluded and this calls into question whether the sample population analyzed is representative of the entire population. Changes made in the manuscript: Methods and Data -Participating centres, page 5, line 31: From these, only patients on haemodialysis who were treated with ESAs were taken into account. Results, page 8, line 55: The patients included in the analysis did not differ from those who were excluded in terms of age structure. The proportion of males was higher in the included patients than in the excluded patients (55% vs. 51%). Racial differences cannot be evaluated because of missing information in the subset of the excluded patients.
Patients were excluded if they did not meet the inclusion criteria as described in the Methods section. To make that clearer, we added the above sentence. Furthermore, we examined possible baseline differences between our sample and the entire collective to test the representativeness.
Methods. The proposed classification scheme is presented in table 2. Given the inclusion criteria, 120 day observation period would result in a minimum of 8.5 hemoglobin observations. The presentation of percentage values out of range complicates the analysis and weights the decision to the denominator which may not be useful. The inclusion/exclusion criteria?s need to be better stated. Is it possible that patients that did not require erythropoietin at some point during the hundred and 20 day observation period were included in the analysis? Changes made in the manuscript: Methods and Data -Proposed classification scheme, page 7, line 38: Three classes with comparable numbers of patients were projected.
The presentation of percentage values merely serves to depict our goal to create three comparably filled classes. The sole criterion for the classification procedure is the number of values out of range. There were no patients included that did not require ESAs.
Statistical analysis. Authors state that individual patient data per period were used to calculate individual mean values. The authors should state the specific data that means were calculated for. The authors have not provided specific information about what is being tested in the statistical analysis. Changes made in the manuscript: Methods and Data -Statistical analysis, page 8, line 3: To summarize data, individual patient data per period were used to calculate individual mean values for all parameters from Table 1 . Methods and Data -Statistical analysis, page 8, line 9: The non-parametric Skillings-Mack test was applied to determine differences between Hb-classes in all variables from Table 1. The null hypothesis that the location parameter of the test variable is equal in all classes is rejected if only one median or distribution significantly differs from the others. This specific test was applied because the data were grouped and except for Hb and EPO the other data items may contain missing values. For ratios and percentages, Pearson's Chi-squared test of homogeneity was used to test for differences between classes. The null hypothesis of homogeneity is rejected if there is a significant deviation between at least two sampling distributions.
We tried to specify the information concerning the statistical analysis.
Results. Interpretation of the data would be improved by identifying those patients that were excluded from analysis and the reason for them being excluded. Changes made in the manuscript: Please see above.
We hope we could give sufficient information on exclusion and inclusion in the Methods section.
How were the 120 day periods determined? Was the starting date uniform for all subjects in the analysis or was it determined on an individual basis? Changes made in the manuscript: Methods and data -Proposed classification scheme, page 7, line 30: The periods were individually determined for each patient. Starting with records from 2010 and ending in 2016 a computerized program identified any existing period of 120 days where the required data were available.
We tried to make that clear.
Information is lost in the analysis by converting darbepoietin to equivalent erythropoietin concentrations. Perhaps the authors should provide analysis separated by agent. If the authors were to perform this analysis then some statement may be made about the different agents and if there is a shift in classification between agents. Changes made in the manuscript: Results, page 10, line 13: Darbepoetin alfa was used in 13% of the medication doses administered. There were no differences in the allocation to Hb classes between those who received Darbepoetin alfa and those treated with rHuEpo.
The results show that for the classification process itself, a differentiation between Darbepoetin alfa and rHuEpo is not of importance. Nonetheless, the classification may be used as an analytical tool for specific questions with regard to the use of different agents.
Results are presented in table 4. It is not known what the statistical comparisons are that are designated with a specific P value. For instance under the line erythropoietin agents, for class I it is listed as a P value of less than 0.001. What is the reference group? Changes made in the manuscript: Table 4 , page 9-10: 4Skillings-Mack test, 5Pearson's Chi-squared test Statement of the authors: We noted the statistical tests applied in Table 4 . We added a description of each test in the Methods section.
Discussion. The authors suggest that the classification system offers a clear description of the outcome of the respective anemia management. However there is no indication that the classification system can distinguish between three different important groups. For group I, three individuals could be categorized the same, but to a physician would be significantly different. For example, two observations below the range, two observations above the range, and one observation below in one observation above are completely different individuals and yet would have the same classification.
At the moment, it is not our aim to distinguish further patient groups within each class. This would be of course more sophisticated but it would complicate the classification system. As a second step beyond the allocation to a class it is certainly useful to take a closer look at the distribution of outliers. But initially it is much easier to handle three classes than to handle three classes plus several subclasses.
Changes made in the manuscript: Discussion, page 10, line 57: In the past, several approaches have been developed that take a further step and propose specific ESA dosing in individual patients.(23,24) Despite promising results none of them has yet reached the status of a standard tool and further research is necessary to identify the best option. Our classification system can deliver valuable information on the performance of such a tool to optimize anaemia management.
We think that our method delivers more sophisticated information which is easier to interpret than mean values and standard deviations for the comparison of patients. Since Hb variability within the boundaries of 10 -12 g/dL is not of concern, our classification provides the opportunity to quantify Hb variability in terms of numbers of outliers in a predefined period of time. This is a simple but very effective method to condense the most important information. Mean values along with their standard deviation don't offer this kind of information in a comparable clarity. The mean values and standard deviations in the three grades of our classification are very close together: Grade 1: 10.8±0.5, Grade 2: 10.8±0.8, Grade 3: 10.4±1.0 and only the standard deviation of Grade 3 (with ≥ 6 outliers!) gives a hint that values are beyond the lower threshold. This is due to the fact that values above and below the thresholds in the calculation of the mean lead to a value within the range while standard deviation gives only a hint but not clear information on the amount of values exceeding the thresholds and therefore offers no clear quantification. The classification may be used as additional information to individual means and standard deviations. As far as the clinical support tool you mentioned is concerned, we clearly stated that all data were originally taken from such a tool, the medical record system cybeREN, which is applied in dialysis centres all over the world, whereby cybeREN offers far more functionality than a traditional medical record system. We explicitly avoided further mentioning of this specific tool because we felt that this would be inappropriate and could be interpreted as hidden advertising. Nonetheless, comparable tools are already in place in many medical centres. What has to be added is an extension to the existing software, which is with respect to the simplicity of the grading system no major challenge.
Comment: My next concern related to the drop from 17,000 patients to about 3000 patients used in the development of the tool. The authors state that about 60% of the patients were on and ESA, but the tool is based on hemoglobin and therefore cannot identify those patients that have anemia and are not properly treated ESA. It would be nice if the authors paired a flow diagram starting with the 17,000 patients and showing the numbers that are eliminated from analysis. Of particular interest is the number of records that did not have the hemoglobin value every 14 days. Changes made in the manuscript: Methods and data, participating centres, page 5, line 48: Figure 1 illustrates the process of selecting patient records.
We added a flow diagram.
Comment: The information on how periods of 120 days were determined is not adequately described.
In the last revision we added: "The periods were individually determined for each patient. Starting with records from 2010 and ending in 2016 a computerized program identified any existing period of 120 days where the required data were available." Please let us know which information is missing in your opinion.
Comment: The authors state in the discussion that the goal is to classify the amount of hemoglobin variability. How is the proposed method better than calculating the mean and standard deviation? By categories information about hemoglobin variability is lost when continuous data, like the globe and variability, are categorized into a subject exists at the boundary between two classifications.
We have answered this question above.
Comment: The authors state that the classification can be integrated into a clinical support system. Can the authors identify a currently existing clinical support system? Statement of the authors: We have answered this question above.
Comment: The development of classification systems in medicine serve the purpose of the identification of a specific disease state and or separating patients into different treatment regimens. How does the proposed system advance our understanding of anemia in chronic kidney disease and its treatment? For instance, can the classification system identify those patients that are nonresponsive to an ESA due to infection? Iron deficiency? Etc.
Our classification offers a longitudinal overview of the past 120 days at a glance and the opportunity to evaluate the long term progression of disease and treatment success. It was not our aim to advance the understanding of anaemia in chronic kidney disease but to provide a tool to aid physicians in their clinical decision making and to facilitate research in the understanding of anaemia in chronic kidney disease. For instance, applying the classification system can help to compare different anaemia protocols or changes in an already existing protocol. Of course it helps to identify patients that are nonresponsive to an ESA due to infection, iron deficiency or generally patients at risk for high variability in Hb values and patients more prone to Hb-cycling. But the detection of the reasons for the assignment of a patient remains the task and responsibility of the physician.
